The Europe Sun
SEE OTHER BRANDS

The most trusted news from Europe

The Europe Sun: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Europe Sun.

Press releases published on April 30, 2025

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

NAARDEN, the Netherlands and MIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients …

Global Uranium Advances Athabasca Basin Exploration with Launch of ZTEM Survey at Astro Project

Global Uranium Advances Athabasca Basin Exploration with Launch of ZTEM Survey at Astro Project

CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- Global Uranium Corp. (CSE: GURN | OTC: GURFF | FRA: Q3J) (the "Company" or “Global”) and Cosa Resources Corp. (TSX-V: COSA) (OTCQB: COSAF) (FSE: SSKU) (“Cosa”) are pleased to announce that geophysical …

Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate

Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate

- Topline data expected in mid-2025 - SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it completed enrollment of its Phase 1 clinical trial evaluating its second-generation oral norovirus …

trivago Delivers 22% Revenue Growth and Raises Full-Year Guidance

trivago Delivers 22% Revenue Growth and Raises Full-Year Guidance

Exhibit 99.1 Operating and Financial Review DÜSSELDORF, GERMANY - April 30, 2025 – trivago N.V. (NASDAQ: TRVG) (the “Company”, “we,” “us,” “our,” or “trivago,”) announced financial results for the first quarter ended March 31, 2025. Highlights: Total …

Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

ASHBURN, Va., April 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that …

Altimmune to Participate in the Citizens Life Sciences Conference

Altimmune to Participate in the Citizens Life Sciences Conference

GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Citizens Life …

ZAMiner Bitcoin Insights on How to Easily Earn Passive Income Every Day

ZAMiner Bitcoin Insights on How to Easily Earn Passive Income Every Day

Image by ZAMiner MIDDLESEX, United Kingdom, April 30, 2025 (GLOBE NEWSWIRE) -- ZA Miner, a UK-based cloud mining platform operated by ZA FUNDINGS LTD, has shared valuable insights into earning passive income through cryptocurrency activities, particularly …

Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader

Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader

Sanofi and CD…

ECARX Announces First Quarter 2025 Unaudited Financial Results

ECARX Announces First Quarter 2025 Unaudited Financial Results

SHANGHAI, April 30, 2025 (GLOBE NEWSWIRE) -- ECARX Holdings Inc. (Nasdaq: ECX) (“ECARX” or the “Company”), a global mobility tech provider, today announced unaudited financial results for the quarter ended March 31, 2025. “The strong momentum we built …

Communiqué de presse : Sanofi et CD&R finalisent la cession d’Opella et créent un leader mondial de la santé grand public

Communiqué de presse : Sanofi et CD&R finalisent la cession d’Opella et créent un leader mondial de la santé grand public

Sanofi et CD…

Parents say stress management most important skill kids aren’t learning

Parents say stress management most important skill kids aren’t learning

FindTutors, in partnership with GoStudent reveals that kids are struggling to cope with exam stress now more than ever This comes as referrals for anxiety in children in the UK have more than doubled since before the pandemic As Stress Awareness Month …

L’innovation, un levier de compétitivité central pour les ESN

L’innovation, un levier de compétitivité central pour les ESN

Évoluant sur un marché tendu et toujours plus concurrentiel, les entreprises de services numériques sont plus que jamais amenées à innover pour se distinguer et gagner en compétitivité. Mais derrière ce mot d’innovation, que se cache-t-il ? Et comment les …

DEBRICHEM® gewinnt IIWCG Achievement Award 2025 für Innovation in der Wundversorgung

DEBRICHEM® gewinnt IIWCG Achievement Award 2025 für Innovation in der Wundversorgung

AMSTERDAM, April 30, 2025 (GLOBE NEWSWIRE) -- DEBRICHEM®, das Spitzenprodukt von DEBx Medical, ist auf der 16. Abu Dhabi Wound Care Conference mit dem IIWCG Achievement Award 2025 für Innovation in der Wundversorgung ausgezeichnet worden. Medien-Snippet. …

DEBRICHEM® se voit décerner le prix 2025 IIWCG Achievement Award récompensant l’innovation dans le domaine du soin des plaies

DEBRICHEM® se voit décerner le prix 2025 IIWCG Achievement Award récompensant l’innovation dans le domaine du soin des plaies

AMSTERDAM, 30 avr. 2025 (GLOBE NEWSWIRE) -- DEBRICHEM®, le produit phare de DEBx Medical, a obtenu le prix IIWCG Achievement Award 2025 récompensant l’innovation dans le domaine du soin des plaies lors de la 16e conférence d’Abu Dhabi sur le soin des …

DEBRICHEM® זכה בפרס ההישגיות של IIWCG לשנת 2025 עבור חדשנות בטיפול בפצעים

DEBRICHEM® זכה בפרס ההישגיות של IIWCG לשנת 2025 עבור חדשנות בטיפול בפצעים

אמסטרדם, April 30, 2025 (GLOBE NEWSWIRE) --  DEBRICHEM®, מוצר הדגל של DEBx Medical, זכה בפרס ההישגיות של IIWCG לשנת 2025 עבור חדשנות בטיפול בפצעים ב-16th Abu Dhabi Wound Care Conference. קטע מדיה הכרה זו, שהוענקה במהלך טקס הפתיחה של ADNEC, מטעם הקבוצה הבין …

RetinAI and FVS Announce CE-MDR Certification for Co-developed AI-based Diabetic Retinopathy Screening Algorithm, LuxIA®

RetinAI and FVS Announce CE-MDR Certification for Co-developed AI-based Diabetic Retinopathy Screening Algorithm, LuxIA®

BERN, Switzerland and MADRID, April 30, 2025 (GLOBE NEWSWIRE) -- RetinAI US Inc. (RetinAI) and Fundación Ver Salud (FVS) are pleased to jointly announce that LuxIA®, their co-developed innovative AI algorithm for Diabetic Retinopathy (DR) screening, has …

London consultancy achieves 91% success rate guiding Kazakhstan’s brightest to top international universities

London consultancy achieves 91% success rate guiding Kazakhstan’s brightest to top international universities

LONDON, April 30, 2025 (GLOBE NEWSWIRE) -- Luminary Education, a London-based educational consultancy with representatives in Almaty and Limassol, is working to bring Kazakhstan’s brightest students to some of the most prestigious American and British …

Audited Results for the year ended 31 December 2024

Audited Results for the year ended 31 December 2024

Audited Results for the year ended 31 December 2024 Serabi Gold plc (“Serabi” or the “Company”) (AIM:SRB, TSX:SBI, OTCQX:SRBIF), the Brazilian focused gold mining and development company, is pleased to announce the Company’s audited results for the year …

Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

Full results from the completed dose escalation part and dose expansion parts of a Phase 1 study evaluating JNJ-1900 (NBTXR3) after induction chemotherapy for patients with locally advanced or borderline resectable pancreatic cancer to be presented by …

Nanobiotix présente les résultats complets de l’étude de Phase 1 évaluant JNJ-1900 (NBTXR3) dans le cancer du pancréas et organise une conférence téléphonique et webcast

Nanobiotix présente les résultats complets de l’étude de Phase 1 évaluant JNJ-1900 (NBTXR3) dans le cancer du pancréas et organise une conférence téléphonique et webcast

L’ensemble des résultats des parties d’escalade et d’expansion de dose de l’étude de Phase 1 évaluant JNJ-1900 (NBTXR3) après chimiothérapie d’induction chez des patients atteints d’un cancer du pancréas localement avancé ou à la limite de la résécabilité …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service